FDA approves Akorn’s generic Voltaren gel
Specialty generic company Akorn has received the Food and Drug Administration’s clearance for its generic Voltaren gel (diclofenac sodium topical gel 1%).
Diclofenac sodium topical gel is indicated for the relief of pain of osteoarthritis of joints amenable to topical treatment, including knees and hands.
The product had a market value of approximately $357 million for the 12 months ended September 2018, according to IQVIA data.
No comments found